



THERASPHERE™ Y-90 Glass Microspheres | **PROACTIF STUDY**

PROACTIF: A prospective, real-world Y-90 study with TheraSphere for the treatment of liver malignancies: Interim data of 168 intrahepatic cholangiocarcinoma (ICC) patients.

THERASPHERE DEMONSTRATED OVERALL SURVIVAL OF 18.1 MONTHS FOR 168 ICC PATIENTS IN PROACTIF

PROACTIF Overview

STUDY OBJECTIVE AND ENDPOINTS

The study aims to gather data on effectiveness, patient quality of life (QoL), and safety with use of TheraSphere Y-90 glass microspheres in real-world clinical settings in France.

Primary Endpoints

Overall survival (OS) from time of TheraSphere treatment and QoL, as assessed using the functional assessment of Cancer Therapy – Hepatobiliary (FACT-Hep) questionnaire.

Key Secondary Endpoints


Grade ≥ 3 AEs, SAEs, tumor response, tumor marker response, subsequent therapy, and dosimetry evaluations.

PROACTIF is the largest, prospective, real-world Y-90 study of primary liver cancer in 1,000+ patients.

Use of TheraSphere in treatment of ICC is outside the labeled indications as safety and effectiveness has not been established.

INTERIM DATA OF 168 ICC PATIENTS ACROSS 32 SITES

OVERALL SURVIVAL



DATA FROM 32 SITES USED CONTEMPORARY TECHNIQUES AND DOSING


63%

MULTI-COMPARTMENT DOSIMETRY

54%

SELECTIVE ADMINISTRATION

REASON FOR TREATMENT



MAJORITY OF PATIENTS HAD SINGLE LESION WITH INDEX LESION > 5CM

PATIENT DEMOGRAPHICS & DISEASE CHARACTERISTICS

Variable	n(%)	Variable	n(%)	Variable	n(%)
Age, median (years)	69	Liver Disease Etiology		Portal Vein Thrombosis	
≥ 18 to < 65	51 (30.4)	No underlying disease	109 (64.9)	Yes	28 (16.7)
≥ 65 to < 75	57 (33.9)	Alcohol	30 (17.9)	Cruoric*	2 (7.1)
≥ 75	51 (30.4)	Hepatitis B/C	11 (5.4)	Tumoral	26 (92.9)
Missing	9 (5.4)	Metabolic	19 (11.3)	ECOG Performance status	
Gender		Unknown/Other	17 (10.1)	0-1	146 (86.9)
Female	88 (52.4)	Total Lesions		2-3	5 (3.0)
Comorbidities (top 5)		1	84 (50.0)	Missing	17 (10.1)
None	47 (28.0)	2-4	54 (32.1)	ALBI Grade	
Alcohol	45 (26.8)	>5	25 (14.8)	1	86 (51.2)
Arterial Hypertension	68 (40.5)	Missing	5 (3.0)	2 or 3	39 (23.2)
Hyperglycemia (diabetes)	41 (21.4)	Index Lesion Diameter		Missing	43 (25.6)
Tobacco	44 (26.2)	Mean size, mm	70.7	Child Pugh	
Liver Disease		>5 cm	99 (67.8)	A	77 (45.8)
Normal/No History	92 (54.8)	Extrahepatic Disease		B	7 (4.2)
Cirrhosis	36 (21.4)	Yes	7 (4.2)	Missing	84 (50.0)
Fibrosis	17 (10.1)	No	158 (94.0)		
Missing	23 (13.7)	Missing	3 (1.8)		

*Non-malignant thrombus

CONCLUSION

Appropriately selected ICC patients treated with TheraSphere demonstrated an overall survival of 18.1 months using Y-90. This dataset helps build foundational real-world data for an under-studied disease state.

This study is sponsored by Boston Scientific. Final results are expected in 2025 and will include full patient population with additional information on quality of life, safety and dosimetry.

Garin E, Brenot-Rossi I, Tilli G et al. Abstract 222.4 Treatment of intrahepatic cholangiocarcinoma with Y-90 glass microspheres in the PROACTIF study. ECIQ 2024 Book of Abstracts. Cardiovasc Intervent Radiol 47 (Suppl 4); 2024. p.60 <https://doi.org/10.1007/s00270-024-03732-x>
Boston Scientific is not responsible for the collection, analysis or reporting of the investigator-sponsored research output which is the sole responsibility of the investigators. Boston Scientific's involvement in investigator-sponsored research is limited to providing financial support for research that advances medical and scientific knowledge about our products. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device.

TheraSphere™ Yttrium-90 Glass Microspheres

INDICATION FOR USE: TheraSphere is indicated for use as selective internal radiation therapy (SIRT) for local tumor control of solitary tumors (1-8 cm in diameter), in patients with unresectable hepatocellular carcinoma (HCC), Child-Pugh Score A cirrhosis, well-compensated liver function, no macrovascular invasion, and good performance status. **CONTRAINDICATIONS:** TheraSphere is contraindicated in patients: whose Tc-99m macroaggregated albumin (MAA) hepatic arterial perfusion scintigraphy shows any deposition to the gastrointestinal tract that may not be corrected by angiographic techniques • who show shunting of blood to the lungs that could result in delivery of greater than 16.5 mCi (0.61 GBq) of Y-90 to the lungs. Radiation pneumonitis has been seen rarely in patients receiving doses to the lungs greater than 30 Gy in a single treatment • in whom hepatic artery catheterization is contraindicated, such as patients with vascular abnormalities or bleeding diathesis • who have pulmonary insufficiency (conventionally defined by an arterial oxygen pressure (PaO₂) of < 60 mmHg or oxygen saturation (SaO₂) of < 90%) or severe liver dysfunction, including hepatic encephalopathy, clinically evident ascites or treatment with diuretics for ascites • with portal vein thrombosis (PVT) Type 4 involvement and lack of Tc-99m MAA deposition on the PVT seen on the Tc-99m MAA imaging with >70% tumor replacement in the liver • with comorbidities or poor overall health (e.g., ECOG performance status rating > 2) which may make the patient a poor candidate for locoregional radiation treatment. • who are pregnant. **WARNINGS:** The following pre-treatment, high-risk factors (disease characteristics) have been associated with serious adverse events deemed possibly related to use of the device: infiltrative tumor type • tumor nodules too numerous to count • AST or ALT > 5 times ULN • bilirubin > 2 mg/dL • tumor volume > 50% combined with albumin < 3 g/dL. Keep the TheraSphere dose vial upright and stored in its lead pot before and during patient treatment, except as required for radiation measurement. Do not open the dose vial acrylic shield prior to patient treatment. Post-treatment, waste materials require caution to prevent contamination and beta shielding due to residual glass microspheres. **PRECAUTIONS: GENERAL PRECAUTIONS:** As in any intra-arterial procedure, aseptic technique should be practiced, and care should be taken to ensure minimum patient anesthesia exposure extraneous to therapeutic objective. • Consideration of patient comorbidities should be used when determining the type and volume of fluid to infuse via catheter to avoid electrolyte imbalance, fluid shift, and hyperglycemia. • It is important to avoid any aggressive arterial procedure that may lead to arterial spasm that impairs TheraSphere distribution into the perfused liver target volume which may lead to underdosing or non-target deposition of TheraSphere. **PRECAUTION IN PATIENTS WITH IMPAIRED LIVER FUNCTION:** No efficacy or safety data from the LEGACY study are available to support the use of the device in patients with Child-Pugh score B or C cirrhosis. **PRECAUTION IN VULNERABLE PATIENTS:** No effectiveness or safety data are available to support the use of the device in children or breast-feeding women. **ENDOCRINE DISRUPTION, CARINOGENICITY, MUTAGENICITY, TOXICITY TO REPRODUCTION:** Ideally the use of this radioactive device in women of childbearing capability should be performed during the first few (approximately 10) days following the onset of menses. **RADIATION SAFETY:** Radioactive products should be used only by healthcare professionals who are qualified by specific training in the safe use and handling of radionuclides and whose experience and training have been approved by the appropriate government agency authorized to license the use of radionuclides. • As in the use of any radioactive material, ensure minimum radiation exposure to the patient extraneous to the therapeutic objective, and to minimize radiation exposure to workers and others in contact with the patient. **RELEASE AND POST-TREATMENT PRECAUTIONS:** Post-treatment patient care: use universal precautions for body fluid contact. Tare Y-90 may be detectable in blood and urine; handle with gloves and dispose as normal body fluids. The radiation field is expected to be less than 1 mrem/h (10 µSv/h) at 3 ft (1 m) from the patient's abdomen. Supplemental shielding and segregation of the patient are not required to maintain exposure to others below regulated limits. • Release instructions: The patient should follow good hygiene (e.g., proper hand washing). Caregivers, family, and others do not require restrictions on patient contact; however, they can minimize their radiation exposure by avoiding prolonged time (>12 hours per day) within 1 ft (0.3 m) of the patient's abdomen for the first week post therapy. Patients should be advised that radiation emitted from the patient may be detectable at security screening (e.g., international travel). • Special precautions post-administration: If the patient requires hospitalization, surgery, medical assessment or treatment regarding any part of their thorax or abdomen within first 2 weeks of treatment, the patient should advise the hospital and treating physician of the Y-90 TheraSphere implant. The physician should consult their radiation safety staff for handling and disposal of liver tissue. • Special liver tissue handling may be required for post-treatment surgery, explant, or transplant since the glass microspheres remain permanently implanted in the liver tissue. Disclosure of the treatment will be required if cremation is considered. **POTENTIAL ADVERSE EVENTS:** The use of this product leads to irradiation of both tumorous and normal liver tissue. As a result, patients with compromised liver function may be at greater risk of liver function impairment and hence could experience complications. Clinical side effects usually occur within the first 4 to 6 weeks after treatment. Based on clinical trial data, literature reviews and post-market surveillance, adverse events potentially associated with treatment using Y-90 microspheres, including TheraSphere, may include the following: Allergic reaction • Altered liver function, acute or chronic • Anorexia • Anxiety • Ascites • Bile Duct Injury • Bleeding/hemorrhage • Chills • Rigors • Cholecystitis (inflammatory or infectious) • Colitis • Death • Dehydration • Diarrhea • Dizziness • Dyspnea • Edema (any location) • Electrolyte abnormalities • Elevated BUN/creatinine • Fall • Fatigue • Fever • Gastrointestinal bleeding / hemorrhage • Gastrointestinal ulcer or ulceration • Hepatic encephalopathy • Hepatorenal failure • Hiccups • Hypertension • Hypotension • Infection (any location) • Liver failure, acute or chronic • Lymphopenia • Malaise • Mood alteration • Muscle weakness • Nausea • Neutropenia • Pain (any location) • Pancreatitis • Platelet count abnormalities • Pleural effusion • Portal hypertension • Pre-existing chronic liver disease decompensation • Pulmonary edema • Pulmonary fibrosis • Radiation hepatitis • Radiation induced disease, acute • Radio Embolization Induced Liver Disease (REILD) • Sepsis • Supraventricular arrhythmia • Thrombosis (arterial or venous) • Tumor inflammation (including tumor edema) • Tumor-lysis syndrome • Vomiting • Weight loss. Complications related to the administration procedure itself may include: Allergic reaction; Arterial injury including vessel dissection • Aspiration pneumonia • Bruising/bleeding/hematoma at site • Constipation/abdominal distension • Fatigue • Flushing • Infection • Nausea • Nerve damage. **CAUTION:** Federal (USA) law restricts this device to sale by or on order of a physician. PI-992004-AA. **Note:** Dose to the liver does not exceed 150 Gy. TheraSphere is a registered trademark of Theragnostics Corporation used under license by Boston Scientific Medical Device Limited, a wholly owned indirect subsidiary of Boston Scientific Corporation.

Boston Scientific
Advancing science for life™

Peripheral Interventions
300 Boston Scientific Way
Marlborough, MA 01752-1234
www.bostonscientific.com

To order product or for more information
contact customer service at 1.888.272.1001.

© 2024 Boston Scientific Corporation
or its affiliates. All rights reserved.

PI-1850705-AA